healthcare

health care

Why Dyax Will Dominate Biotech News on Wednesday

Dyax Corp. (NASDAQ: DYAX) is almost certain to dominate the biotech news flow on Wednesday. The company announced positive data on Tuesday evening from the Phase 1b clinical study of the ...
Read Full Story »
Ebola Virus

Ebola Finances Coming Back in the News

Within the past week a there has been a resurgence in Ebola-related companies in the news. This doesn’t bring the scare that it once did in the fall, but two ...
Read Full Story »
Prescription drugs

Why a PBM Acquisition Is Taking UnitedHealth to All-Time Highs

UnitedHealth Group Inc. (NYSE: UNH) is making a $12.8 billion acquisition. Investors are used to seeing an acquirers' shares fall when they announce mergers, but this deal is quite different. ...
Read Full Story »
health care

UBS Raises Price Targets on 4 Top Health Care Providers

If there has been one group stocks that has delivered for investors this year it has been the managed care organizations (MCO) that are the top health care providers in ...
Read Full Story »
generic drugs

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

It is a nice change sometimes when the prognosticators on Wall Street, who tend to follow each other's lead, are not only right, but investors come out on top. Almost ...
Read Full Story »
152498601

Alzheimer’s Drug Could Be Instant Blockbuster for Biogen Idec

Over 5 million Americans are currently living with Alzheimer’s disease, and it is the sixth leading cause of death in the United States, according to the Alzheimer’s Association. Alzheimer’s, along ...
Read Full Story »
health care

How Large Is Prothena’s Market Opportunity?

Parkinson’s disease is a degenerative disorder that affects 50,000 to 60,000 new cases every year. There may even be 7 million to 10 million people living with this disease worldwide. ...
Read Full Story »
ten dollar bills

How the Tekmira Secondary Offering Could Help the Company

The Ebola scare is back but maybe not in the sense of the actual disease. Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), one of the top names in the Ebola drug arena, is ...
Read Full Story »
DNA

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases. A ...
Read Full Story »
Pills

4 Top Pharmaceutical Stocks to Buy for Market Safety

Tuesday's big downward move reminded everybody that while things look encouraging for the stock market long term, momentum stocks tend to get absolutely eviscerated when a big volatility jump helps ...
Read Full Story »
462542665

Just How Expensive Is the Pharmacyclics Buyout?

Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official ...
Read Full Story »
Biotechnology word cloud

Novogen Makes Big Step In Fighting Brain Cancer

Novogen Limited (NASDAQ: NVGN) confirmed Wednesday morning that one of its lead candidate products, TRXE-009, has shown potential to become an important new therapy for both adult and pediatric brain ...
Read Full Story »
biotech

The 5 Most Loved Biotech Stocks of Portfolio Managers

With the market continuing to grind higher, and the memories of the first time the Nasdaq hit 5,000 getting a fair amount of airplay and commentary, the question for most ...
Read Full Story »
health care

Key Analyst Weighs In on Boston Scientific Acquisition

Boston Scientific Corp. (NYSE: BSX) announced that it entered into a definitive agreement with Endo International PLC (NASDAQ: ENDP) to acquire its American Medical Systems urology portfolio. The deal calls for ...
Read Full Story »
biotech

Are Mylan Earnings Enough?

Monday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share (EPS) and ...
Read Full Story »